L. Fredrik Jarskog, M.D.

E-mail: jarskog@med.unc.edu

Phone: (919) 843-7683

Fax: (919) 966-8994

Education:

B.A., Johns Hopkins University

M.D., Wake Forest University School of Medicine

Residency, Psychiatry, University of North Carolina Hospitals

Fellowship, Psychiatry Research, University of North Carolina at Chapel Hill

Summary Statement:

Dr. Jarskog’s research is focused on the pathophysiology and treatment of schizophrenia. He conducts clinical trials for patients with schizophrenia, testing drugs with novel mechanisms of action, with a particular focus on treatments for cognitive impairment and for weight gain and metabolic deficits associated with antipsychotic drugs.  He also studies factors that help regulate neuronal viability, such as neurotrophins (e.g BDNF) and apoptotic regulatory proteins (e.g. Bcl-2), and how these may contribute to the neuropathology of schizophrenia.

Representative Publications:

1)   Buchanan RW, Keefe RSE, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC,   Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry. (Epub 2010 Dec 7)

2)   Rosenfeld A, Lieberman JA, Jarskog LF. Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. Schizophr Bull. (doi:10.1093/schbul/sbq015)

3)   Kayser J, Tenke CE, Kroppmann CJ, Fekri S, Alschuler DM, Gates NA, Gil R, Harkavy-Friedman JM, Jarskog LF, Bruder GE. Current source density (CSD) old/new effects during recognition memory for words and faces in schizophrenia and in healthy adults. Int J Psychophysiol. 2010; 75:194-210.

4)   Glantz LA, Gilmore JH, Overstreet DH, Salimi K, Lieberman JA, Jarskog LF. Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. Schizophr Res. 2010; 118:292-299.

5)   Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode psychosis: a comparative review. CNS Drugs. 2009; 23:837-855.

6)   Cox ET, Brennaman LH, Gable KL, Hamer RM, LaMantia A-S, Lieberman JA, Gilmore JH, Maness PF, Jarskog LF. Developmental regulation of neural cell adhesion molecule (NCAM) in human prefrontal cortex. Neuroscience. 2009;162:96-105.

7)   Glantz LA, Gilmore JH, Hamer RM, Lieberman JA, Jarskog LF. Synaptophysin and PSD-95 in the human prefrontal cortex from mid-gestation into early adulthood. Neuroscience. 2007; 149:582-591.